| Name | Title | Contact Details |
|---|
ValueOptions Inc., the nation's largest independent behavioral health care and wellness company, specializes in management for all behavioral health issues, and mental health and chemical dependency diagnoses.
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.
Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.
Caring physicians, caring for people. cCARE, Californias largest private practice oncology group, focuses on compassion, prevention, research and wellness.
MediPharm Labs was created in 2015 by a handful of industry experts in Ontario. With the medicinal benefits of cannabis firmly established – and with a global patient market demanding quality cannabis oil – MediPharm Labs was born. While initially exploring options to cultivate cannabis plant, MediPharm Labs came to recognize the opportunity for a select focus on cannabis concentrates. MediPharm Labs set out to master this area of production, and rely on the many cultivating experts to provide quality raw materials. In 2016, MediPharm labs submitted an application to Health Canada for approval to distribute medicinal cannabis oil. Proudly, MediPharm Labs was one of the first Licensed Producer applications in history to apply for license that did not include the cultivation of cannabis. The key to MediPharm Labs` unrivaled quality is our best possible use of modern technology and innovative extraction techniques. MediPharm Labs produces cannabis oil that is pharmaceutical grade and and meets the specific quality and purity requirements. The team behind MediPharm Labs have proven industry experience in the areas of pharmaceutical extraction, processing and quality assurance. In 2018, MediPharm Labs is gearing up to commence distribution to our Health Canada approved business partners and make history. The response has been enormous, positive and heartening. Medicinal cannabis has arrived – and through our partners we will provide patients with access to pure, consistent and safe cannabis oil. MediPharm Labs commenced construction of a world-class extraction facility in Australia in June 2018. MediPharm Labs Australia is a subsidiary of MediPharm Labs Inc. and the companies` first expansion outside of Canada. MediPharm Labs Australia completed its application process with the federal Office of Drug Control in February 2018 to extract and import medical cannabis products in Australia.